Saturday 5 October 2024

BRIEF—GSK terminates deal with Immatics

Biotechnology
21 November 2022

More on this story...

Biotechnology
Imfinzi misses endpoint in Phase III bladder cancer trial
6 March 2020
Biotechnology
Lilly and Germany's CureVac agree I-O deal worth up to $2 billion
18 October 2017
Biotechnology
Big pharma pair fail with I-O trial
28 November 2017
Biotechnology
Imfinzi plus tremelimumab again fails in Stage IV NSCLC trial
21 August 2019


Companies featured in this story

More ones to watch >


Today's issue

Cannabis legislation on the way, but some say pain will remain in Spain
Pharmaceutical
Cannabis legislation on the way, but some say pain will remain in Spain
4 October 2024
Pharmaceutical
Trevi updates on clinical progress for chronic cough treatment
4 October 2024
Biotechnology
Recordati acquires rights to Enjaymo
4 October 2024
Biotechnology
Kurma clocks up 140 million euros in first closing of new fund
4 October 2024
Pharmaceutical
EMA/PRAC latest meeting highlights
4 October 2024
Pharmaceutical
Non-opioid meds for addiction treatment remain key unmet need
4 October 2024
Pharmaceutical
NHS England plans phased obesity drug launch
4 October 2024

Company Spotlight

A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.






Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze